MedTrace Logo

Efficacy and Safety of Leningrado 5 Association in the Treatment of Hypertension

NCT03814148 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2021-02-24

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of Leningrado 5 association on the treatment of hypertension.

Conditions

  • Arterial Hypertension

Interventions

DRUG

LENINGRADO 5 association

1 coated sustained-release tablet, oral, once a day.

DRUG

Natrilix® SR

1 coated sustained-release tablet, oral, once a day.

OTHER

Natrilix SR Placebo

1 coated sustained-release tablet, oral, once a day.

OTHER

Leningrado 5 association Placebo

1 coated sustained-release tablet, oral, once a day.

Sponsors & Collaborators

  • EMS

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-30
Primary Completion
2020-06-30
Completion
2020-09-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03814148 on ClinicalTrials.gov